
Where Is Alembic Pharmaceuticals Share Price Headed Over the Next 3 Years?
Alembic Pharmaceuticals share price Rs 837 (10 July 2026). 52W high Rs 1,065, low Rs 635. Market cap Rs 16,471 Cr. 2030 scenario range Rs 1,000 to Rs 1,630.
Updated: 13 Jul 2026 • 12:34 pm
Posted by:
The Alembic Pharmaceuticals share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 837 on 10 July 2026, within a 52 week range of Rs 635 to Rs 1,065. This article lays out a scenario based Alembic Pharmaceuticals share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.
Click Here – Get Free Investment Predictions
Alembic Pharmaceuticals Company Overview
Alembic Pharmaceuticals is a vertically integrated pharma company with a strong India branded formulations business, a large US generics portfolio and multiple USFDA approved manufacturing facilities. Understanding the business model is the first step in framing any credible Alembic Pharmaceuticals share price forecast, because the durability of earnings ultimately decides where the stock trades.
| Company | Alembic Pharmaceuticals |
| NSE Ticker | APLLTD |
| CMP (10 July 2026) | Rs 837 |
| 52 Week High | Rs 1,065 |
| 52 Week Low | Rs 635 |
| Market Cap | Rs 16,471 Cr |
| Stock PE | 22.6 |
| Book Value | Rs 289 |
| ROE | 13.4% |
| ROCE | 12.6% |
| Dividend Yield | 1.31% |
Where Does Alembic Pharmaceuticals Share Price Stand Today?
The stock currently trades about 21 percent below its 52 week high of Rs 1,065, which means the market has already tempered some of its optimism. For anyone building a Alembic Pharmaceuticals share price forecast, this correction matters for the Alembic Pharmaceuticals share price forecast starting point, because entry valuations have a large bearing on 3 year returns.
At the current price, Alembic Pharmaceuticals commands a market capitalisation of Rs 16,471 Cr and trades at a price to earnings multiple of 22.6. The company generates a return on equity of 13.4% and a return on capital employed of 12.6%, which places it in the category of businesses with moderate return ratios. These numbers anchor the Alembic Pharmaceuticals share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.
Alembic Pharmaceuticals Share Price Forecast: Key Growth Drivers for the Next 3 Years
Four forces are likely to shape the Alembic Pharmaceuticals share price forecast between now and 2030, and together they explain most of the dispersion in this Alembic Pharmaceuticals share price forecast. Each is discussed below with its likely direction of impact.
Earnings Trajectory and Return Ratios
Stock prices ultimately follow earnings. With moderate return ratios at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Alembic Pharmaceuticals share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.
Structural Tailwinds in Indian Pharmaceuticals
The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Alembic Pharmaceuticals, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.
Within the space, investors often benchmark Alembic Pharmaceuticals against peers such as Torrent Pharmaceuticals, Ajanta Pharma and Alkem Laboratories on growth and valuations before forming a view on the Alembic Pharmaceuticals share price forecast.
Company Specific Catalysts
The bull case for Alembic Pharmaceuticals rests on a rich ANDA pipeline for the US market, new facility ramp ups and steady growth in its India specialty portfolio. If these play out on schedule, the Alembic Pharmaceuticals share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.
Macro Environment and Liquidity
The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Alembic Pharmaceuticals share price forecast, while global risk aversion would do the opposite to the Alembic Pharmaceuticals share price outlook.
Alembic Pharmaceuticals Share Price Forecast 2027, 2028 and 2030: Scenario Analysis
The table below presents a scenario based Alembic Pharmaceuticals share price forecast using compounded annual growth assumptions applied to the current market price of Rs 837. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.
| Year | Bear Case | Base Case | Bull Case | Assumption |
|---|---|---|---|---|
| 2027 | Rs 890 | Rs 965 | Rs 1,050 | 4% to 16% CAGR on CMP |
| 2028 | Rs 925 | Rs 1,060 | Rs 1,210 | 4% to 16% CAGR on CMP |
| 2030 | Rs 1,000 | Rs 1,290 | Rs 1,630 | 4% to 16% CAGR on CMP |
In the base case scenario of this Alembic Pharmaceuticals share price forecast, the 2030 level works out to roughly Rs 1,290, implying steady compounding from today’s levels. The bull case of Rs 1,630 assumes a rich ANDA pipeline for the US market delivers ahead of expectations, while the bear case of Rs 1,000 captures a scenario where growth stalls. That is an outcome band of about 19 percent to 95 percent over the period.
Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast
Bull Case vs Bear Case for Alembic Pharmaceuticals Share Price
The Bull Case
The optimistic Alembic Pharmaceuticals share price forecast assumes a rich ANDA pipeline for the US market, new facility ramp ups and steady growth in its India specialty portfolio. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 1,630 by 2030.
The Bear Case
The cautious view centres on the fact that US generic price erosion and regulatory inspection outcomes at key plants remain the principal uncertainties. If these pressures dominate, the Alembic Pharmaceuticals share price forecast would skew toward the lower band and the stock could stagnate near Rs 1,000 even by 2030, underperforming broader indices.
Key Risks That Could Change the Alembic Pharmaceuticals Share Price Outlook
- Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Alembic Pharmaceuticals share price forecast.
- Valuation risk: At a PE of 22.6, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
- Sector risk: US generic price erosion and regulatory inspection outcomes at key plants remain the principal uncertainties.
- Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
- Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.
Is Alembic Pharmaceuticals Worth Watching for the Long Term?
For long term investors, the relevant question is not just where the Alembic Pharmaceuticals share price forecast lands in 2030 or what any single Alembic Pharmaceuticals share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around a rich ANDA pipeline for the US market gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.
Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Alembic Pharmaceuticals share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.
Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals share price live.
Conclusion
The Alembic Pharmaceuticals share price forecast for the next 3 years spans Rs 1,000 to Rs 1,630 by 2030 under the scenarios discussed, with a base case near Rs 1,290. Any credible Alembic Pharmaceuticals share price forecast must be updated as facts change, and the path will be decided by earnings delivery, a rich ANDA pipeline for the US market and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What is the Alembic Pharmaceuticals share price forecast for the next 3 years?
Ans. The Alembic Pharmaceuticals share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 1,000 in the bear case to Rs 1,630 in the bull case, with a base case near Rs 1,290, depending on earnings delivery and market conditions.
What is the Alembic Pharmaceuticals share price forecast for 2027?
Ans. For 2027, the scenario range works out to Rs 890 to Rs 1,050, with a base case around Rs 965. This assumes compounding on the current price of Rs 837 and is illustrative, not a guaranteed outcome.
What is the Alembic Pharmaceuticals share price forecast for 2028?
Ans. The 2028 scenario range is Rs 925 to Rs 1,210, with the base case near Rs 1,060. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.
What is the current share price of Alembic Pharmaceuticals?
Ans. As of 10 July 2026, Alembic Pharmaceuticals trades at around Rs 837 on the NSE, within a 52 week range of Rs 635 to Rs 1,065. Prices change continuously during market hours, so check live quotes before acting.
Is Alembic Pharmaceuticals a good stock for the long term?
Ans. Alembic Pharmaceuticals has a credible long term story built on a rich ANDA pipeline for the US market, but it also carries risks since US generic price erosion and regulatory inspection outcomes at key plants remain the principal uncertainties. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.
What is the Alembic Pharmaceuticals share price outlook for 2030?
Ans. The Alembic Pharmaceuticals share price outlook for 2030 spans Rs 1,000 to Rs 1,630 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.
What are the key risks to the Alembic Pharmaceuticals share price forecast?
Ans. The main risks are execution delays, valuation compression from the current PE of 22.6, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.
Recent Articles

Cigniti Technologies Share Price: What Could the Next 3 Years Look Like?
13 July 2026

Where Will Bank of India Share Price Be in the Next 3 Years?
13 July 2026

Canara HSBC Life Insurance Company Share Price Rising Today: Stock Jumps 3.13% to Rs 148.54
13 July 2026

Dabur India Share Price: What Could the Next 3 Years Look Like?
13 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Cigniti Technologies Share Price: What Could the Next 3 Years Look Like?
Where Will Bank of India Share Price Be in the Next 3 Years?
Canara HSBC Life Insurance Company Share Price Rising Today: Stock Jumps 3.13% to Rs 148.54
Dabur India Share Price: What Could the Next 3 Years Look Like?
Where Will Chalet Hotels Share Price Be in the Next 3 Years?
Popular this week
Cigniti Technologies Share Price: What Could the Next 3 Years Look Like?
Where Will Bank of India Share Price Be in the Next 3 Years?
Canara HSBC Life Insurance Company Share Price Rising Today: Stock Jumps 3.13% to Rs 148.54
Dabur India Share Price: What Could the Next 3 Years Look Like?
Where Will Chalet Hotels Share Price Be in the Next 3 Years?

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





